Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Letizia Gianoncelli, Marcello Tiseo, Paolo Pedrazzoli, Antonio Maconi, Federico Cappuzzo, Stefano Frega, Maria Pagano, Giulia Pasello, Matteo Perrino, F. Zanelli, Maria Bonomi, Carmine Pinto, Filippo de Marinis, Luca Boni, Federica Grosso, Armando Santoro, Candida Bonelli, Marina Chiara Garassino, Paolo Andrea Zucali, Francesco Grossi, Giovanni Luca Ceresoli, Erika Gervasi, Hector Soto Parra
Summary Background There is a preclinical rationale for inhibiting angiogenesis in mesothelioma. We aimed to assess the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab combined with gemcitabine in patients with pretreated malignant pleur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78597edc6a57d0d326a538c014d92e8a
http://hdl.handle.net/11383/2125715
http://hdl.handle.net/11383/2125715
Autor:
Domenico Amoroso, Alessandro Bertolini, Maria Rita Migliorino, Andrea Luciani, Adolfo Favaretto, Alba A. Brandes, Paolo Bidoli, Giuseppe Tonini, Cesare Gridelli, Filippo de Marinis
Publikováno v:
Anticancer Research. 37:2457-2464
Background/aim The management of elderly patients with advanced non-squamous NSCLC includes several strategies. Patients and methods Patients (≥70 years) were randomly assigned to bevacizumab (7.5 mg/kg i.v. on day 1) plus gemcitabine (1,200 mg/m2
Autor:
Massimo Di Maio, Federico Cappuzzo, Francesco Perrone, Luigi De Petris, Filippo de Marinis, Fortunato Ciardiello, Robert Pirker, Rolf A. Stahel, Panagiotis Fidias, Luis Paz-Ares, Chandra P. Belani, Andrea Ardizzoni, Cesare Gridelli
Publikováno v:
Lung Cancer. 76:269-279
Several randomized trials have recently investigated the role of maintenance treatment for patients with advanced non-small-cell lung cancer (NSCLC) with responding or stable disease after completion of first-line chemotherapy. Maintenance strategy h
Autor:
Oscar Alabiso, Vincenzo Adamo, Santi Barbera, Filippo de Marinis, R. Morena, Andrea Ardizzoni, Paolo Maione, Cesare Gridelli, Paola Venturino, Sandro Barni, Vito Lorusso, Vittorio Gebbia, E. Piazza, Calogero Buscarino, Nicoletta Zilembo, Alberto Caprioli, Maurizio Marangolo, Lucio Crinò, Riccardo Pela, Gianfranco Filippelli
Publikováno v:
Lung Cancer. 74:462-468
Lung cancer is the most common cancer in the world today, in terms of both incidence and mortality. Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers, and the majority of people diagnosed with NSCLC have locally advanced o
Autor:
Ferdinando Riccardi, Filippo de Marinis, Luca Boni, Vittorio Gebbia, Davide Dondi, Teresa Gamucci, Francesco Grossi, Enzo Galligioni, Francesco Ferraù, M. Nardi, Orazio Caffo, Luca Moscetti
Publikováno v:
Cancer Chemotherapy and Pharmacology. 69:369-375
The aim of this study was to determine the activity and toxicity of two sequential chemotherapy regimens in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).Eighty-eight chemonaive patients with stage IIIB/IV NSCLC were randomi
Autor:
Patrick Peterson, Cesare Gridelli, Sergio Ricci, Yan D. Zhao, Astra M. Liepa, Filippo de Marinis, Lucio Crinò, Maurizio Tonato, Giorgio V. Scagliotti, M. Rinaldi
Publikováno v:
Journal of Thoracic Oncology. 4:1568-1571
IntroductionAlthough histology has not consistently been associated with treatment outcome in advanced non-small cell lung cancer, a recent phase III trial comparing pemetrexed plus cisplatin and gemcitabine plus cisplatin (GC) demonstrated better ef
Publikováno v:
Lung Cancer. 66:141-149
Pemetrexed, a new cytotoxic agent, is a potent inhibitor of thymidylate synthase and other folate-dependent enzymes. Firstly, pemetrexed was approved in combination with cisplatin for the treatment of malignant pleural mesothelioma. Successively, it
Autor:
Thierry Le Chevalier, Matti Aapro, Frances A. Shepherd, Karen Kelly, Cesare Gridelli, Corey J. Langer, Christian Manegold, Massimo Di Maio, Filippo de Marinis, Andrea Ardizzoni, Rafael Rosell, Luigi De Petris, Francesco Perrone, Lodovico Balducci
Publikováno v:
Journal of Clinical Oncology. 23:3125-3137
The best treatment for elderly patients with advanced non–small-cell lung cancer (NSCLC) is still debated. To guide clinical management of these patients and suggest the priorities for clinical research in this field, an International Expert Panel
Autor:
Cesare Gridelli, Olga Martelli, Luigi Portalone, Stefano Treggiari, Maria Rita Migliorino, Enrico Cortesi, Carlo Crispino, Fabrizio Nelli, Luigi Brancaccio, Filippo De Marinis
Publikováno v:
Cancer. 98:1707-1715
BACKGROUND The objective of the current study was to define the activity and tolerability, as well as the influence on resectability, of the combination of gemcitabine, paclitaxel, and cisplatin (GTP) as induction chemotherapy for patients with Stage